Australian preclinical-stage drug discovery and development company, Nyrada Inc. (ASX: NYR), in its cholesterol-lowering drug development program to treat hypercholesterolemia, made a big step forward towards replacing expensive current injections with the first-ever oral pill.
Nyrada’s Cholesterol-lowering study indicates that in healthy human white blood cells, NYR’s PCSK9 inhibitor (NYX-PCSK9i) demonstrates equivalency to the two FDA approved, marketed monoclonal PCSK9 antibody drugs, Repatha® and Praluent®, the combined FY2019 sales of which was over US$900 million.
Significantly, the results were confirmed both with and without the presence of a statin (Mevastatin), unlocking the potential to develop combined PCSK9-statin single-pill treatment for high LDL cholesterol.
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.